SCHEMBL1480964

SCHEMBL1480964

CCn1cc(-c2ccc(C(=O)NC)cc2)nc1/C=C/c1ccc(-c2ccc(OCCCC(=O)O)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.42
PLK1 P53350 2/20 0.42
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
ALB P02768 1/20 0.39
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
RARB P10826 3/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
CYSLTR2 Q9NS75 2/20 0.38
CYSLTR1 Q9Y271 2/20 0.38
KDM1A O60341 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480967 1.00 PPARA (0.42) PPARAPLK1ALDH1A1LMNAGAA
SCHEMBL1481944 0.92 PLK1 (0.41) PLK1ALDH1A1LMNAGAAMAPT
SCHEMBL1481948 0.92 PLK1 (0.41) PLK1ALDH1A1LMNAGAAMAPT
SCHEMBL12754209 0.91 RARB (0.47) PPARAALBCASP3SENP8SENP7
SCHEMBL1481721 0.89 PPARA (0.52) PPARAALBCASP3SENP8SENP7
SCHEMBL1481717 0.89 PPARA (0.52) PPARAALBCASP3SENP8SENP7
SCHEMBL1481604 0.88 CASP3 (0.50) PPARAALBCASP3SENP8SENP7
SCHEMBL1481600 0.88 CASP3 (0.50) PPARAALBCASP3SENP8SENP7
SCHEMBL12754201 0.88 PPARA (0.43) PPARAALBCASP3SENP8SENP7
SCHEMBL1481363 0.88 PPARA (0.49) PPARAALBCASP3SENP8SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ PPARA 2236/4885PLK1 3205/4885ALDH1A1 710/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ PPARA 2236/4885PLK1 3205/4885ALDH1A1 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.